• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

来自正常和肿瘤性甲状腺组织的多细胞球体作为测试多激酶抑制剂效果的合适模型。

Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.

作者信息

Cirello Valentina, Vaira Valentina, Grassi Elisa Stellaria, Vezzoli Valeria, Ricca Dario, Colombo Carla, Bosari Silvano, Vicentini Leonardo, Persani Luca, Ferrero Stefano, Fugazzola Laura

机构信息

Endocrine Unit, Fondazione IRCCS Ca' Granda, 20122 Milan, Italy.

Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.

出版信息

Oncotarget. 2017 Feb 7;8(6):9752-9766. doi: 10.18632/oncotarget.14187.

DOI:10.18632/oncotarget.14187
PMID:28039458
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5354768/
Abstract

Multicellular three-dimensional (3D) spheroids represent an experimental model that is intermediate in its complexity between monolayer cultures and patients' tumor. In the present study, we characterize multicellular spheroids from papillary (PTC) and follicular (FTC) thyroid cancers and from the corresponding normal tissues. We show that these 3D structures well recapitulate the features of the original tissues, in either the differentiated and "stem-like" components. As a second step, we were aimed to test the effects of a small multikinase inhibitor, SP600125 (SP), previously shown to efficiently induce cell death in undifferentiated thyroid cancer monolayer cultures. We demonstrate the potent effect of SP on cell growth and survival in our 3D multicellular cultures. SP exerts its main effects through direct and highly significant inhibition of the ROCK pathway, known to be involved in the regulation of cell migration and β-catenin turnover. Consistently, SP treatment resulted in a significant decrease in β-catenin levels with respect to basal conditions in tumor but not in normal spheroids, indicating that the effect is promisingly selective on tumor cells.In conclusion, we provide the morphological and molecular characterization of thyroid normal and tumor spheroids. In this 3D model we tested in vitro the effects of the multikinase inhibitor SP and further characterized its mechanism of action in both normal and tumor spheroids, thus making it an ideal candidate for developing new drugs against thyroid cancer.

摘要

多细胞三维(3D)球体代表了一种实验模型,其复杂性介于单层培养物和患者肿瘤之间。在本研究中,我们对来自乳头状(PTC)和滤泡状(FTC)甲状腺癌以及相应正常组织的多细胞球体进行了表征。我们表明,这些3D结构很好地概括了原始组织在分化和“干细胞样”成分方面的特征。第二步,我们旨在测试一种小型多激酶抑制剂SP600125(SP)的作用,该抑制剂先前已证明能有效诱导未分化甲状腺癌单层培养物中的细胞死亡。我们证明了SP对我们的3D多细胞培养物中细胞生长和存活的强大作用。SP通过直接且高度显著地抑制ROCK途径发挥其主要作用,已知该途径参与细胞迁移和β-连环蛋白周转的调节。一致地,与肿瘤球体的基础条件相比,SP处理导致β-连环蛋白水平显著降低,但在正常球体中未出现这种情况,这表明该作用对肿瘤细胞具有有前景的选择性。总之,我们提供了甲状腺正常和肿瘤球体的形态学和分子表征。在这个3D模型中,我们在体外测试了多激酶抑制剂SP的作用,并进一步表征了其在正常和肿瘤球体中的作用机制,从而使其成为开发抗甲状腺癌新药的理想候选者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/cd80eb5ea88b/oncotarget-08-9752-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/c331d991be91/oncotarget-08-9752-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/e914b72227ea/oncotarget-08-9752-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/895935a63c40/oncotarget-08-9752-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/b26bd1dec793/oncotarget-08-9752-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/1b3588e4335a/oncotarget-08-9752-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/cd80eb5ea88b/oncotarget-08-9752-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/c331d991be91/oncotarget-08-9752-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/e914b72227ea/oncotarget-08-9752-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/895935a63c40/oncotarget-08-9752-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/b26bd1dec793/oncotarget-08-9752-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/1b3588e4335a/oncotarget-08-9752-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f2/5354768/cd80eb5ea88b/oncotarget-08-9752-g006.jpg

相似文献

1
Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.来自正常和肿瘤性甲状腺组织的多细胞球体作为测试多激酶抑制剂效果的合适模型。
Oncotarget. 2017 Feb 7;8(6):9752-9766. doi: 10.18632/oncotarget.14187.
2
SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.SP600125通过对ROCK和p53通路的选择性作用,对未分化甲状腺癌具有显著的抗癌潜力。
Oncotarget. 2015 Nov 3;6(34):36383-99. doi: 10.18632/oncotarget.5799.
3
Tumor and normal thyroid spheroids: from tissues to zebrafish.肿瘤与正常甲状腺球体:从组织到斑马鱼
Minerva Endocrinol. 2018 Mar;43(1):1-10. doi: 10.23736/S0391-1977.17.02610-4. Epub 2017 Jan 31.
4
Extracellular Superoxide Dismutase Expression in Papillary Thyroid Cancer Mesenchymal Stem/Stromal Cells Modulates Cancer Cell Growth and Migration.甲状腺乳头癌间充质干细胞/基质细胞中细胞外超氧化物歧化酶的表达调节癌细胞的生长和迁移。
Sci Rep. 2017 Feb 20;7:41416. doi: 10.1038/srep41416.
5
Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.甲状腺癌对酪氨酸激酶抑制剂舒尼替尼的持续临床反应。
Anticancer Drugs. 2008 Jun;19(5):547-52. doi: 10.1097/CAD.0b013e3282fc6cf7.
6
NITRIC OXIDE SYNTHASE ACTIVITY AND ITS CONCENTRATION IN THE TISSUES OF HUMAN THYROID CARCINOMAS.人甲状腺癌组织中一氧化氮合酶活性及其浓度
Fiziol Zh (1994). 2016;62(3):9-19. doi: 10.15407/fz62.03.009.
7
Tumorigenic and metastatic activity of human thyroid cancer stem cells.人甲状腺癌细胞癌干细胞的致瘤性和转移性活性。
Cancer Res. 2010 Nov 1;70(21):8874-85. doi: 10.1158/0008-5472.CAN-10-1994. Epub 2010 Oct 19.
8
Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo.表皮生长因子在体外和体内均可增强滤泡状甲状腺癌和乳头状甲状腺癌的增殖、迁移及侵袭能力。
J Clin Endocrinol Metab. 1994 Aug;79(2):401-8. doi: 10.1210/jcem.79.2.8045955.
9
Multikinase inhibitors in thyroid cancer.甲状腺癌中的多激酶抑制剂
Ann Oncol. 2012 Sep;23 Suppl 10:x328-33. doi: 10.1093/annonc/mds356.
10
A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.一种细胞周期蛋白依赖性激酶抑制剂,地西他滨在甲状腺癌临床前治疗模型中的应用。 (注:原文中“dinaciclib”翻译可能有误,结合语境推测可能是“dasatinib”,这里按原文翻译为地西他滨,供参考。准确的应根据正确药物名翻译)
PLoS One. 2017 Feb 16;12(2):e0172315. doi: 10.1371/journal.pone.0172315. eCollection 2017.

引用本文的文献

1
NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Development of 3D organoid models to study aggressive thyroid cancers.晚期甲状腺癌的新见解:从机制到治疗:用于研究侵袭性甲状腺癌的3D类器官模型的开发
Eur Thyroid J. 2025 Jul 2;14(4). doi: 10.1530/ETJ-24-0392. Print 2025 Aug 1.
2
Characterization of EpCAM in thyroid cancer biology by three-dimensional spheroids in vitro model.通过三维球体体外模型对甲状腺癌生物学中EpCAM的特征分析。
Cancer Cell Int. 2024 Jun 4;24(1):196. doi: 10.1186/s12935-024-03378-2.
3
Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.

本文引用的文献

1
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model.癌症研究中的三维培养系统:聚焦肿瘤球模型。
Pharmacol Ther. 2016 Jul;163:94-108. doi: 10.1016/j.pharmthera.2016.03.013. Epub 2016 Apr 8.
2
Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group.临床试验中的相关性研究:国际甲状腺肿瘤学组的立场声明
J Clin Endocrinol Metab. 2015 Dec;100(12):4387-95. doi: 10.1210/jc.2015-2818. Epub 2015 Sep 29.
3
SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.
间变性甲状腺癌球体作为临床前模型用于测试治疗方法。
J Exp Clin Cancer Res. 2024 Mar 19;43(1):85. doi: 10.1186/s13046-024-03009-8.
4
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.探索诱导多能干细胞在癌症研究和治疗中的广阔前景。
Mol Cancer. 2023 Nov 28;22(1):189. doi: 10.1186/s12943-023-01873-0.
5
Different Expression of Thyroid-Specific Proteins in Thyroid Cancer Cells between 2-Dimensional (2D) and 3-Dimensional (3D) Culture Environment.甲状腺癌细胞在二维(2D)和三维(3D)培养环境中的甲状腺特异性蛋白表达不同。
Cells. 2022 Nov 10;11(22):3559. doi: 10.3390/cells11223559.
6
Utilizing Three-Dimensional Culture Methods to Improve High-Throughput Drug Screening in Anaplastic Thyroid Carcinoma.利用三维培养方法改善间变性甲状腺癌的高通量药物筛选
Cancers (Basel). 2022 Apr 7;14(8):1855. doi: 10.3390/cancers14081855.
7
Microgravity, Stem Cells, and Cancer: A New Hope for Cancer Treatment.微重力、干细胞与癌症:癌症治疗的新希望
Stem Cells Int. 2021 Apr 29;2021:5566872. doi: 10.1155/2021/5566872. eCollection 2021.
8
Thyroid Cancer Stem-Like Cells: From Microenvironmental Niches to Therapeutic Strategies.甲状腺癌干细胞:从微环境龛位到治疗策略
J Clin Med. 2021 Apr 1;10(7):1455. doi: 10.3390/jcm10071455.
9
Cancer Stem Cells in Thyroid Tumors: From the Origin to Metastasis.甲状腺肿瘤中的癌症干细胞:从起源到转移。
Front Endocrinol (Lausanne). 2020 Aug 25;11:566. doi: 10.3389/fendo.2020.00566. eCollection 2020.
10
The effects of microgravity on differentiation and cell growth in stem cells and cancer stem cells.微重力对干细胞和肿瘤干细胞分化和细胞生长的影响。
Stem Cells Transl Med. 2020 Aug;9(8):882-894. doi: 10.1002/sctm.20-0084. Epub 2020 Apr 30.
SP600125通过对ROCK和p53通路的选择性作用,对未分化甲状腺癌具有显著的抗癌潜力。
Oncotarget. 2015 Nov 3;6(34):36383-99. doi: 10.18632/oncotarget.5799.
4
Targeted therapies in advanced differentiated thyroid cancer.晚期分化型甲状腺癌的靶向治疗。
Cancer Treat Rev. 2015 Sep;41(8):690-8. doi: 10.1016/j.ctrv.2015.06.002. Epub 2015 Jun 17.
5
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.索拉非尼抑制甲状腺癌细胞内的信号通路,诱导细胞周期停滞和细胞死亡,无论其组织学来源或BRAF突变状态如何。
BMC Cancer. 2015 Mar 26;15:184. doi: 10.1186/s12885-015-1186-0.
6
Spherical cancer models in tumor biology.肿瘤生物学中的球形癌症模型。
Neoplasia. 2015 Jan;17(1):1-15. doi: 10.1016/j.neo.2014.12.004.
7
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway.肥大细胞通过 IL-8-Akt-Slug 通路诱导人甲状腺癌细胞发生上皮间质转化和干细胞特征。
Oncogene. 2015 Oct 1;34(40):5175-86. doi: 10.1038/onc.2014.441. Epub 2015 Jan 26.
8
Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.分化型甲状腺癌中的端粒酶:启动子突变、表达及定位
Mol Cell Endocrinol. 2015 Jan 5;399:288-95. doi: 10.1016/j.mce.2014.10.019. Epub 2014 Oct 27.
9
Integrated genomic characterization of papillary thyroid carcinoma.甲状腺乳头状癌的综合基因组特征分析
Cell. 2014 Oct 23;159(3):676-90. doi: 10.1016/j.cell.2014.09.050.
10
FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics.使用小分子抑制剂Y15抑制黏着斑激酶(FAK)可降低甲状腺癌细胞系的活力、克隆形成能力和细胞黏附,并与靶向治疗药物产生协同作用。
Oncotarget. 2014 Sep 15;5(17):7945-59. doi: 10.18632/oncotarget.2381.